Navigation Links
Researchers discover brain cancer treatment using genetic material from bone marrow cells

DETROIT In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers at Henry Ford Hospital have discovered a novel approach for treatment of tumor. Specifically, the research team found that introducing genetic material produced by MSCs, significantly reduced a particularly resistant form of malignant brain tumor in living lab rats.

"This is the first foray of its type in experimental cancer therapy, and it represents a highly novel and potentially effective treatment," says Michael Chopp, Ph.D., scientific director of the Henry Ford Neuroscience Institute and vice chairman of the Department of Neurology at Henry Ford Hospital. The research is published in the current issue Cancer Letters.

"I think this is an important and very novel approach for the treatment of cancers, and in this particular case the treatment of glioma," says Dr. Chopp. "We have been at the forefront of developing microRNAs as a means to treat disease, such as cancer and neurological injury.

"This study shows it is effective in the living brain, and may even lend itself to specific cancer therapy, customized for the individual patient," Chopp adds

Chopp and his colleagues focused their efforts on glioma, by far the most common type of malignant brain tumor, and one with a notably poor prognosis for survival.

Tumor cells were surgically implanted in the brains of anesthetized male lab rats and allowed to grow for five days. The tumors then were injected with exosomes containing molecules of a microRNA called miR-146b found in earlier Henry Ford research to have a strong effect on glioma cells.

Exosomes are microscopic "lipid bubbles" that once were thought to carry and get rid of "old" proteins that were no longer needed by the body. After they were more recently found to also carry RNA, whole new fields of study were suggested including groundbreaking work by Henry Ford researchers.

In their rat study, Chopp and his colleagues used MSC bone marrow cells to produce the exosomes containing the miR-146b they injected into the cancerous tumors.

Five days after this treatment, the rats were euthanized and their brains were removed, prepared for study, and examined. Tumor size was measured using computer software.

"We found that one injection of exosomes containing miR-146b five days after tumor implantation led to a significant reduction in tumor volume at 10 days after implant," Chopp says. "Our data suggest that miR-146b elicits an anti-tumor effect in the rat brain, and that MSCs can be used as a "factory" to generate exosomes genetically altered to contain miR-146b to effectively treat tumor. "


Contact: Dwight Angell
Henry Ford Health System

Related biology news :

1. Notre Dame researchers are using new technologies to combat invasive species
2. University of Montreal researchers discover how drug prevents aging and cancer progression
3. Researchers question evaluation methods for protected areas in the Amazon
4. Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device
5. Researchers find novel mechanism regulating replication of insulin-producing beta cells
6. Researchers find novel way plants pass traits to next generation
7. Ludwig cancer researchers honored among first class of fellows in AACR Academy
8. Researchers issue forecast for moderate New England red tide in 2013
9. Researchers spot molecular control switch for preterm lung disorders
10. Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug
11. Dartmouth researchers invent real time secondhand smoke sensor
Post Your Comments:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology: